Introduction {#Sec1}
============

Management strategies for acute respiratory distress syndrome (ARDS) continue to evolve as mortality for Pediatric ARDS (PARDS) still remains high \[[@CR1], [@CR2]\] despite efforts to improve outcomes with several lung protective techniques. High-frequency oscillatory ventilation (HFOV), which has often been employed as a "rescue" therapy in hypoxemic respiratory failure has shown to reduce ventilator induced lung injury (VILI) in several experimental studies \[[@CR3], [@CR4]\].

Historically, Arnold et al. in 1994 conducted one of the earliest randomised controlled studies to determine the survival benefit of HFOV in 70 pediatric patients, comparing HFOV to conventional mechanical ventilation (CMV). They showed that while there was no survival benefit, significantly fewer patients remained dependent on supplemental oxygen at 30 d in the group on HFOV \[[@CR4]\]. This study was done at a time when low tidal volume strategy was not widely practiced.

The theoretical advantage of HFOV lies in the combination of a continuous distending pressure that keeps the lung recruited, thus preventing cyclical atelectrauma, while small tidal volumes (1--4 ml/kg) ventilate at a 3 to 15 Hz frequency \[[@CR3]\]. However, these conjectures were not translated into survival benefit as demonstrated by recent studies in adults -- Oscillation in ARDS (OSCAR) \[[@CR5]\] and Oscillation for ARDS treated early (OSCILLATE) \[[@CR6]\]. The OSCAR study showed similar all cause 30-day mortality in the HFOV (41.7%) and CMV (41.1%) groups but higher use of sedatives and muscle relaxants in the HFOV group, while the OSCILLATE study showed a higher mortality in the HFOV group (47%) as compared to the controlled ventilation group (35%). There was also greater requirement of inotropic and vasopressor support in patients randomised to HFOV, and these factors prompted the OSCILLATE study to be halted after an interim 500-patient analysis. Optimal HFOV settings, timing of transition, disease specific benefits and patient related factors influencing the final outcome on HFOV are still under considerable debate and so, the uncertainty regarding its benefit in the pediatric population still prevails with survival rates ranging from 40 to 80% \[[@CR7]--[@CR11]\].

Similar to centres where extracorporeal membrane oxygenation (ECMO) is not available, authors use HFOV in cases of PARDS with refractory hypoxemia. Hence, the authors reviewed their institutional experience with HFOV in children in terms of outcomes and aimed to identify the predictors of survival in these children.

Material and Methods {#Sec2}
====================

A retrospective review of patients admitted to an 8-bedded PICU of a tertiary care referral centre was conducted to determine the survival to hospital discharge in patients who were transitioned to HFOV as "salvage" therapy. The study protocol was approved by the Institutional Ethics committee.

Records of children admitted in pediatric intensive care unit (PICU) from October 2014 through September 2017 were reviewed.

Children less than 18 y of age with PARDS \[[@CR2]\] who were managed with HFOV after failing conventional ventilation were included -- \[Oxygenation Index (OI) \> 20 despite high positive end-expiratory pressure (PEEP) (\>10 cm H~2~O) with peak pressures exceeding 30 cm H~2~O on Pressure Control - Synchronised Intermittent Mandatory Ventilation (PC-SIMV), or P~plat~ \> 28--32 cm H~2~O on Volume Control - SIMV mode. As the study was of retrospective nature, the patients were retrospectively categorised into mild, moderate and severe PARDS as per PALICC (Pediatric Acute Lung Injury Consensus Conference) definition \[[@CR2]\]. Arterial blood gas (ABG) reports and ventilatory settings mentioned in patient records were used to calculate OI and PaO~2~/FiO~2~ (P/F ratio).

Patients were identified by reviewing case records of all patients who received mechanical ventilation for ARDS or respiratory failure due to any etiology. Clinical data were collected from case records: age, gender, diagnosis and etiology of respiratory failure, Pediatric index of mortality 2 score (PIM2), Sequential organ failure assessment score (SOFA score), length of stay (LOS) and mortality. Hemodynamic parameters such as heart rate, mean blood pressure \[mean arterial pressure (MAP)\] and doses of vasoactive agents were collected immediately prior to HFOV and upon initiation, and then at 24 and 48 h after initiation. OI, PaO~2~/FiO~2~, mean airway pressure (mPaw), amplitude, frequency, FiO~2~, PCO~2~, and pH upon initiation of HFOV, and then at 12, 24, and 48 h, and then immediately prior to discontinuation of HFOV were recorded. Ventilatory parameters on CMV and while on HFOV at 12, 24 and 48 h were also noted. Those with incomplete records or missing data were excluded from the study.

OI was calculated: OI = (Mean airway pressure × FiO~2~ × 100)/PaO~2~. P/F ratio was defined as ratio of partial pressure of oxygen in arterial blood to fraction of inspired oxygen (PaO~2~/FiO~2~). OI and P/F ratio were calculated at 12 h, 24 h, and 48 h using arterial blood gas reports.

Vasotrope inotrope score (VIS) was calculated as described by Wernovsky \[[@CR12]\]. Wernowsky inotrope score (IS) = Dopamine dose (μg/kg/min) + Dobutamine dose (μg/kg/min) + 100 × epinephrine dose (μg/kg/min).

Vasoactive-inotropic score (VIS) \[[@CR12]\] = Inotrope score + 10 X Milrinone dose (μg/kg/min) + 10,000 × Vasopressin dose (U/kg/min) + 100 × Norepinephrine dose (μg/kg/min).

Ventilatory settings studied on CMV were PEEP, Paw, fraction of inspired oxygen (FiO~2~), and those on HFOV were pressure amplitude (ΔP), mPaw and FiO~2~.

Early HFOV was defined as initiation of HFOV within 24 h of intubation \[[@CR13]\].

The primary outcome was survival to hospital discharge. Secondary outcome measures were determining the effect of variables such as OI, P/F ratio, VIS score, cumulative doses of midazolam, fentanyl and muscle relaxant in CMV and HFOV as predictors of survival. The authors also compared outcomes between early initiation of HFOV (within 24 h of intubation) *vs*. late HFOV in terms of survival, duration of mechanical ventilation and duration of ICU stay.

The ventilation strategy used in patients of ARDS is as per authors' unit protocol \[[@CR14]\]. All children who are shifted to the PICU for ARDS receive an initial trial of non-invasive mechanical Ventilation or CMV depending upon clinical condition or severity of ARDS. The pressure controlled- synchronised intermittent mandatory ventilation (PC-SIMV) or the pressure regulated volume control (PRVC) modes are used on conventional mechanical ventilators (Draeger Evita 2, Maquet Servo *i*, or Viasys Avea). A lung-protective ventilation strategy with small tidal volumes (5--8 ml/kg predicted body weight) and controlled pressures (inspiratory plateau pressures lower than 28--30 cm H~2~O) are usually targeted. Recruitment manoeuvres are not routinely performed before transitioning patients to CMV or from CMV to HFOV. Patients are shifted to HFOV when patients remain in refractory hypoxemia with plateau pressure surpassing 30 cm H~2~O inspite of permissive hypercapnia and permissive hypoxemia (Targeting saturations 88--92%).

For high-frequency oscillatory ventilation, the authors used Sensormedics 3100A ventilator, which is a piston driven device with an active expiratory phase (Sensor Medics, Yorba Linda, CA).

The FiO~2~ is usually set as 100% at the beginning of HFOV. Frequency is set according to the weights as per standard convention between 6 and 10 Hz - 10 Hz (600 BPM) for young infants, for children between 6 and 10 kg, we used 8 Hz, and for children \>10 kg, 6 Hz for an initial setting \[[@CR11]\].

One of the two strategies of mPaw (Mean airway pressure) setting is usually followed by the treating physicians-mPaw equal to the mPaw on the conventional ventilator or mPaw set 5--8 cm H~2~O above the last mPaw on CMV (High volume strategy) \[[@CR13]\] and then increased stepwise targeting a saturation 88--92% and PaO~2~--60 mmHg. The amplitude of oscillation is titrated to maintain the vibration of chest wall down to the lower abdomen/thighs. Patients are considered for switching back to CMV when the HFOV settings are tapered (FiO~2~ \< 50%, mPaw 10--20 cm H~2~O, and amplitude of oscillation \<30 cm H~2~O) with acceptable arterial blood gas.

All patients on HFOV are sedated or paralysed as per discretion of treating physician (titration to Penn State Sedation Scale \[[@CR15]\]) with a continuous infusion of midazolam, fentanyl or vecuronium.

As per unit protocol, arterial blood gas measurements are performed periodically; if tracheal suctioning had been planned, the samples are drawn usually 20--30 min after tracheal suctioning.

Shock management is done as per Surviving Sepsis Campaign Guidelines \[[@CR16]\].

Data were extracted using a structured performa. Microsoft Excel^®^ was used to manage the data and Stata ver. 13 (Stata Corp., College Station, TX). Descriptive statistics were used to report the experience with use of HFOV. Survivors and non-survivors were compared for baseline variables using the two-tailed t-test or Mann-Whitney U test for continuous data, and the Fisher test for qualitative data. Variables that were not normally distributed were log transformed before analysis. Relationships between continuous variables were analyzed by linear regression. Multiple logistic regression was used to evaluate the independent risk factors. The results of the logistic regression analysis are reported as odds ratios (OR) with 95% confidence intervals (CI). *p*-values less than 0.05 were considered statistically significant.

Results {#Sec3}
=======

Thirty-eight children with PARDS were transitioned to HFOV during the study period for refractory hypoxemia; four were excluded from analysis as they were ventilated for less than 12 h; of the remaining thirty-four patients, 8 (23.52%) survived. Table [1](#Tab1){ref-type="table"} summarizes the demographic, illness severity score, etiology and complications of the patients. All patients fulfilled criteria for severe ARDS by the time they were initiated on HFOV.Table 1Patient characteristicsDemographic characteristicsTotal (*n* = 34)Age (months)19.5 (4, 84)Gender (male), n (%)18 (52.94)Weight (kg)8.8 (3.5, 17)Predicted mortality using PIM2 score25.2 (11.4, 34.3)SOFA score7 (4, 10.5)Pre-existing lung disease, n (%)10 (29.4)Interstitial lung diseases, n (%)5 (14)Primary immunodeficiency, n (%)3 (8.82)Congenital heart diseases, n (%)2 (5.88)Viral pneumonia, n (%)5 (14.71)Bacterial pneumonia (Community acquired/hospital acquired), n (%)25 (73.53)Complications -- Airleaks  Pneumothorax, n (%)9 (26)  Pneumomediastinum, n (%)4 (11.7)Treatment with other "Rescue" therapies  Inhaled nitric oxide, n (%)3 (8.8)  Corticosteroids, n (%)2 (5.8)  Prone position, n (%)2 (5.8)Values are median (IQR) unless indicated*IQR* Interquartile range; *PIM2* Pediatric index of mortality 2 score; *SOFA score* Sequential organ failure assessment score

Early HFOV was initiated in 16 (47%) children; there was no difference in mortality between those started on early HFOV *vs*. those initiated late. However, the length of mechanical ventilation was significantly shorter in those who were put on early HFOV \[median 202.5 h; IQR (90.75, 303) *vs*. 347 h (235, 454), *p* = 0.015\] (Table [2](#Tab2){ref-type="table"}).Table 2Univariate analysis of survivors *vs*. non-survivorsVariablesSurvivors (*n* = 8)Non-survivors (*n* = 26)*p* valueMedian \[IQR\]Median \[IQR\]Gas exchange and ventilator parameters on CMV, before switching to HFOV  pH7.24 (7.05, 7.34)7.16 (7.12, 7.28)0.98  PaO~2~57.25 (38.55, 92.95)58.3 (32.9, 68)0.42  PaCO~2~ (mmHg)62.35 (52.5, 108)59 (49, 89.8)0.65  P/F ratio65.25 (44.1, 92.95)65.2 (38.9, 76.4)0.64  OI29.5 (23.8, 31.5)38.5 (30, 53)0.1  PEEP (cm H~2~O)10.5 (8, 11.5)13 (10, 15)0.1  MAP (cm H~2~O)21.5 (15.5, 25.5)22.5 (20, 28.5)0.6  Time in CMV before HFOV (hours)30.25 (12, 96)62 (12, 144)0.4HFOV parameters  Duration of HFOV (hours)100 (95, 141)119 (47.5, 192)0.73  Early HFOV, \[n(%)\]4 (50)12 (46.15)0.85  pH soon after initiation of HFOV7.34 (7.22, 7.38)7.22 (7.14, 7.31)0.09  PaO~2~ on HFOV at 12 h (mmHg)73.2 (56.6, 100.3)69.6 (52.6, 97.9)0.99  PaO~2~ on HFOV at 24 h (mmHg)67.15 (60.25, 86.9)62 (51.3, 78.7)0.36  PaO~2~ on HFOV at 48 h (mmHg)68.55 (59.95, 89.45)66.7 (46.2, 84.8)0.34  PaCO~2~ after initiation of HFOV (mmHg)61.75 (43.15, 70)56.2 (49.4, 83.2)0.62  P/F ratio on HFOV at 12 h87.7 (77.56, 137)81 (52.6, 108)0.34  P/F ratio on HFOV at 24 h111.5 (77.15, 149.5)87.68 (51.8, 156.5)0.55  P/F ratio on HFOV at 48 h110 (92.85, 170)73.7 (54.7, 111)0.22  Initial MAP on HFOV higher than CMV (cm H~2~O) \[n(%)\]5 (62.5)15 (68.18)0.77  MAP on HFOV initiation (cm H~2~O)24.5 (18.5, 30)25.5 (20, 28)0.76  MAP on HFOV at 24 h (cm H~2~O)22.75 (15.5, 31)24 (20, 30)0.99  MAP on HFOV at 48 h (cm H~2~O)17.5 (14.5, 26)22 (18, 28)0.3  OI on HFOV at 12 h20.3 (18, 32)28.2 (23.4, 40.9)0.25  OI on HFOV at 24 h18.4 (10.15, 26.25)30 (16.8, 39.3)0.42  OI on HFOV at 48 h15 (11, 26.7)28.5 (16.8, 47.8)0.15  Lowest FiO~2~ achieved42.5 (35, 47.5)74 (45, 100)0.003  PaO~2~ on lowest FiO~2~ achieved (mmHg)72.35 (60.1, 88.95)63.05 (52.5, 86.8)0.5Hemodynamic scores  Vasotrope inotrope score on CMV12.5 (0, 35)10 (0, 30)0.78  Vasotrope inotrope score on HFOV at 24 h22.5 (1.25, 44.5)15 (0, 43)0.87  Vasotrope inotrope score on HFOV at 48 h4.25 (1.25, 17.5)15 (0, 80)0.29Patient -- ventilator interaction factors  Cumulative dose of midazolam on CMV (mg)57.6 (38.15, 144)61 (11.85, 129.2)0.54  Cumulative dose of midazolam on HFOV (mg)103.85 (68.5, 138.52)127.6 (27.6, 287.5)0.96  Cumulative dose of fentanyl on CMV (mg)7.1 (0.13, 65.5)0.47 (0, 1.8)0.34  Cumulative dose of fentanyl on HFOV (mg)6.9 (0.9, 78.3)1.3 (0.3, 5.1)0.18  Cumulative dose of muscle relaxant on HFOV (mg)5.8 (0, 54)0.5 (0, 39)0.71  Length of Mechanical Ventilation (hours)265 (199, 504)282 (144, 404)0.51  ICU length of stay (days)20 (12, 265)10.85 (5, 20)0.06*CMV* Conventional mechanical ventilation; *HFOV* High-frequency oscillatory ventilation; *MAP* Mean airway pressure; *OI* Oxygenation Index; *P/F ratio* PaO~2~ /FiO~2~ ratio; *PEEP* Positive end expiratory pressure

The median (IQR) duration of CMV before transitioning to HFOV was higher in non-survivors \[62 h (12, 144) *vs*. 30.25 h (12, 96), *p* = 0.4\], and non-survivors had a higher OI at initiation of HFOV \[38.5 (30, 53) *vs*. 29.5 (23.8, 31.5), *p* = 0.1\].

The median mPaw used on HFOV just after transitioning from CMV was 24.5 cm H~2~O \[IQR (18.5, 30)\]. Airleaks (pneumothorax and pneumomediastinum) were noted in 11 patients (32.3%).

Improvement in the OI along with increase in PaO~2~/FiO~2~ (P/F ratio) between 24 - 48 h of initiation of HFOV were associated with survival. Though not statistically significant, authors found that survivors trended a higher P/F ratio and a lower OI at 12, 24 and 48 h (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Trends in (**a**) oxygenation index, (**b**) mean airway pressures, (**c**) P/F ratios in survivors (blue) *vs*. non-survivors (red). X-axis shows time (hours) at baseline on CMV followed by HFOV. Data are displayed as mean and error bars represent SEM at each time-point. *P* value was non-significant for these parameters. *CMV* Conventional mechanical ventilation; *HFOV* High-frequency oscillatory ventilation; *P/F* PaO~2~/FiO~2~

Compared to the non-survivors, the survivors had an early tapering of vasotropes and inotropes and were almost off the medications by 48 h \[median (IQR) VIS at 48 h: 4.25 (1.25, 17.5) *vs*. 15 (0, 80)\], however, the cumulative doses of analgesics (fentanyl infusion) \[6.9 mg (0.9, 78.3) *vs*. 1.3 mg (0.3, 5.1), *p* = 0.18\] and muscle relaxants (vecuronium) \[5.8 mg (0, 54) *vs*. 0.5 mg (0, 39), *p* = 0.71\] were higher in survivors *vs*. non-survivors during the entire duration of HFOV.

Multivariate logistic regression analysis showed the following independent predictive factors associated with survival: SOFA score (OR 0.39, 95% CI 0.17--0.93; *p* = 0.03), Percent change in P/F ratio after 24 h on HFOV (OR 0.93, 95% CI 0.88--1.00; *p* = 0.04), OI at 48 h of initiation of HFOV (OR 0.67, 95% CI 0.47--0.97; *p* = 0.03) after adjusting for gender and OI at 24 h.

Discussion {#Sec4}
==========

The authors have shared here, their experience with HFOV in children with respiratory failure whose oxygenation did not improve on conventional mechanical ventilation.

In the present cohort, survivors and non-survivors had similar gas exchange parameters during CMV, yet differences in oxygenation parameters and ventilatory settings (MAP) became evident within 48 h after transition to HFOV. The present results show that while both survivors and non-survivors trended an improvement in OI along with increase in P/F ratio within 24 h of initiation of HFOV, only the survivors continued with sustained improvement upto 48 h of ventilation. Thus, based on the OI and P/F ratio, the response to HFOV between 24 and 48 h of ventilation could help identify potential survivors. Even though both groups were transitioned to HFOV with an OI \> 25, the survivors achieved OI \~ 20 within 12 h of initiation, and P/F ratios more than 100 within 24 h. This aspect may guide the physician to re-evaluate ventilation strategy or employ other rescue therapies in patients who are not likely to respond to HFOV. Also lower PEEP on CMV and shorter duration of CMV before initiation of HFOV was associated with survival. The present results corroborate the findings in previous studies which link improved oxygenation parameters with survival \[[@CR17]--[@CR20]\].

The survival rate for "salvage" HFOV in the present study was 23.4%. Severe PARDS is associated with higher mortality (61%) in resource limited settings if associated with multiorgan dysfunction and severe sepsis \[[@CR21]\], and thus have lesser chances of responding to salvage therapies. All the non-survivors had non-pulmonary multi-organ dysfunction and refractory septic shock confounding the survival rate -- which could be attributed to the nosocomial infections associated with prolonged mechanical ventilation (median = 12 d in non-survivors). Similar settings with comparable patient population have reported survival rates close to present one -- Pinzon et al. \[[@CR22]\] recorded a mortality rate of 52%, 28 d after the onset of ARDS. The median OI in present study for starting HFOV in survivors *vs*. non-survivors was \[29.5 (23.8, 31.5) *vs*. 38.5 (30, 53), *p* = 0.1\] and this could be attributed to a late decision to transition to HFOV. All the survivors had non-bacterial pneumonia as cause of PARDS namely -- Severe malaria, iatrogenic aspiration pneumonia with pneumothorax, late presenting Total anomalous pulmonary venous connection (TAPVC), dengue shock syndrome, and influenza (H1N1) pneumonia. This is in contrast to a study by Babbitt et al. \[[@CR23]\] who reported statistically improved survival in both bacterial and viral pneumonia in their retrospective study from North America. They identified a higher SOFA score at admission, a lower percentage increase in P/F ratio at 24 h and a higher OI at 48 h of initiation of HFOV as being associated with increased odds of death in HFOV recipients after adjusting for predictor variables (gender and OI at 24 h). Comporota et al. \[[@CR19]\] in their study of patients with ARDS reported an improvement in P/F ratio \> 38% at any time within 72 h of HFOV as being good predictor of survival at 30 d. In the present study, a higher percentage increase in P/F ratio at 48 h was identified in survivors as compared to non-survivors \[58% (1.15, 65.3) *vs*. 27% (4, 59.9), *p* = 0.3\] though not statistically significant, however, the percentage decrease in OI at 48 h of HFOV was similar in both groups \[36.5% (0.4, 64.3) *vs*. 35.5% (10, 54.3), *p* = 0.5\] -- this could be explained by the different levels of MAP used and poor recruitability of lungs in non-survivors.

Bateman et al. \[[@CR24]\] reported early HFOV to be associated with longer duration of mechanical ventilation and a similar risk of mortality compared to CMV/Late HFOV. Gupta et al. \[[@CR13]\] reported in their retrospective observational study that in survivors, early use of HFOV within 24 h of acute respiratory failure was associated with a shorter length of ventilation (16.3 *vs*. 25.5 d, *p*\< 0.001) and shorter ICU LOS (19.6 *vs*. 31.1 d, *P* \< 0.001) compared with late use of HFOV. The present study showed similar mortality in groups with early *vs*. late HFOV, and a shorter duration of mechanical ventilation (MV) and ICU LOS in the group started on early HFOV \[202.5 h (90.75, 303) *vs*. 374 h (235, 454), *p* = 0.015\] and \[11 d (7.5, 15.5) *vs*. 20 d (8, 26), *p* = 0.05\].

Spontaneous breathing during HFOV has shown to improve oxygenation and regional ventilation \[[@CR25], [@CR26]\]. However, while it may be feasible in neonates and small children, the benefits decline at higher inspiratory flows as in older children. Hence use of sedative -- analgesics and neuromuscular blockade titrated to tolerance of mechanical ventilation with appropriate drug holidays is standard norm in most PICUs. The present results show a higher VIS at 24 h in survivors *vs*. non-survivors \[22.5 (1.25, 44.5) *vs*. 15 (0, 43)\] with a rapid taper in the subsequent 24 h in survivors against prolonged requirement of inotropes and vasopressors by non-survivors at 48 h \[VIS at 48 h: 4.25 (1.25, 17.5) *vs*. 15 (0, 80), *p* = 0.29\], and this could be explained by the higher cumulative doses of vasodilating fentanyl and muscle relaxant infusion used in the survivors, which may have curtailed work of imposed breathing \[[@CR27]\] that can arise from asynchrony or high inspiratory flow demands. A reduction in cardiac output upon initiation of HFOV, as demonstrated in infants in two pediatric studies may have also accounted for increased inotropic requirements in the immediate 24 h period \[[@CR27], [@CR28]\].

Limitation of the present study is its retrospective design and small sample size. The authors were not able to demonstrate the effect that recruitment manoeuvres may have had in influencing outcome due to lack of data. They have reported experience with HFOV as a salvage therapy, when conventional ventilation failed to maintain gas-exchange. In absence of availability of ECMO, HFOV may be an option.

Conclusions {#Sec5}
===========

Survival in the cohort of pediatric ARDS patients treated with HFOV could be predicted by using trends of OI -- with survivors showing a more rapid decline in OI between 24 and 48 h of initiation compared to non-survivors. In absence of facilities for ECMO, HFOV may be used as salvage therapy in severe PARDS.
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